about
HCV-related nervous system disordersClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisLong survival and clinical stability in Marburg's variant multiple sclerosisBenign course of tumour-like multiple sclerosis. Report of five cases and literature review.Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.Switching multiple sclerosis patients with breakthrough disease to second-line therapy.Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob diseaseRegional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis PatientsEfficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityAssessing subjective quality of life domains after multiple sclerosis diagnosis disclosure.Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases.Brentuximab vedotin: axonal microtubule's Apollyon.Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome.Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy.Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis.Risk factors for post-polio syndrome among an Italian population: a case-control study.Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study.Prognostic factors of acute partial transverse myelitisSensory integration balance training in patients with multiple sclerosis: A randomized, controlled trialUp-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients
P50
Q22306452-1DBBD800-2076-426F-966D-CCA995AC95DEQ26771635-C5C0ED07-285F-4EA3-ADA7-CA6C75E3C514Q28282181-427CF225-D493-4D94-872D-ACE0C10E30FAQ30577463-64CA1F2B-5B54-4FA3-B9AC-E60A16D6BB41Q30712257-BEAC111C-FBD6-4ADA-872B-B334C57F2E20Q30869048-D5C149C0-F236-4C33-AC6F-CDD4CC804511Q31024615-575BE732-FBC6-458A-8E27-19FFCADC9460Q33815455-BE882E43-05FD-4CC7-8AE7-1C948D3CE40CQ34856849-13890348-084E-47C1-BE78-A2D825BD0F10Q35297556-E4CBAF4D-9304-43D3-BDEF-43D1E7CC56C5Q35744057-3EF251BE-C294-4399-A19D-F3A9788DC728Q37235845-F9418464-300A-4441-841C-95C98CDBAD76Q37321449-9758A902-AEAC-4DFD-9875-CE4A303A7388Q37969082-E6C5D302-639A-48F6-B244-F85B4DACD9AFQ41067770-79DD3059-0079-4C62-BF2C-0E2C939B3683Q43014241-D5ED766C-679D-440C-8CCB-B3E1B8C6D262Q43067218-AC8B7688-F685-48D3-A8C1-2C1EB8EB054CQ44130928-EEE023FD-3807-45E8-B3FE-9FDAB47691FAQ47833195-460A5CC9-0703-4ADF-B8C7-6CDFB382F245Q48241520-93EC7632-D7B4-4773-9D4A-011E75640EE2Q48444465-948845C7-D663-4DDE-8DB9-EB4285024C5EQ50551208-D509449A-1CE7-4A4C-A8DC-357D4623A46EQ51041061-22E833F6-A4FC-4A6C-A837-2FDB7A84A95DQ51236987-B5186B40-869D-43DD-873E-3C728A69F8A8Q51368039-637E1183-A5B1-44FF-9748-0EAF3552A7A9Q54277562-98BBC012-4846-4EB3-8C5C-0180B5435BEBQ85335455-C5ABD089-5C0B-4036-A4C1-80FAC10225EDQ86519820-5BC34511-E1F1-49E0-BEA3-184F91651F14Q95309974-364A3CFB-4CF6-4DF1-9463-F694643262D1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alberto Gajofatto
@ast
Alberto Gajofatto
@en
Alberto Gajofatto
@es
Alberto Gajofatto
@nl
type
label
Alberto Gajofatto
@ast
Alberto Gajofatto
@en
Alberto Gajofatto
@es
Alberto Gajofatto
@nl
prefLabel
Alberto Gajofatto
@ast
Alberto Gajofatto
@en
Alberto Gajofatto
@es
Alberto Gajofatto
@nl
P106
P1153
26221345200
P21
P31
P496
0000-0001-6539-0458